M&A Deal Summary

Integra LifeSciences Holdings Acquires Acclarent

On December 13, 2023, Integra LifeSciences Holdings acquired medical products company Acclarent from Ethicon Endo-Surgery for 275M USD

Acquisition Highlights
  • This is Integra LifeSciences Holdings’ 38th transaction in the Medical Products sector.
  • This is Integra LifeSciences Holdings’ 3rd largest (disclosed) transaction.
  • This is Integra LifeSciences Holdings’ 38th transaction in the United States.
  • This is Integra LifeSciences Holdings’ 9th transaction in California.

M&A Deal Summary
Date 2023-12-13
Target Acclarent
Sector Medical Products
Buyer(s) Integra LifeSciences Holdings
Sellers(s) Ethicon Endo-Surgery
Deal Type Divestiture
Deal Value 275M USD

Target

Acclarent

Menlo Park, California, United States
Acclarent is a medical device company dedicated to the development of innovative devices providing new technologies to further meet the needs of ENT patients. It has developed the Balloon Sinuplasty system: a novel, endoscopic, catheter-based technology used by surgeons for sinusitis patients. Acclarent was formed in 2004 and is based in Menlo Park, California.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Integra LifeSciences Holdings

Princeton, New Jersey, United States
Category Company
Founded 1989
Sector Medical Products
Employees3,946
Revenue 1.5B USD (2023)
DESCRIPTION

Integra LifeSciences Holdings is a major medical technology, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedic extremity surgery, neurosurgery, and reconstructive and general surgery. Integra LifeSciences Holdings was founded in 1989 and is based in Princeton, New Jersey.

DEAL STATS #
Overall 45 of 45
Sector (Medical Products) 38 of 38
Type (Divestiture) 12 of 12
State (California) 9 of 9
Country (United States) 38 of 38
Year (2023) 1 of 1
Size (of disclosed) 3 of 27
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2022-12-01 SIA

Chicago, Illinois, United States

SIA is a commercial-stage medical device company, committed to raising the standard of care in plastic, reconstructive, and general surgery and lowering systemic costs through “for surgeon, by surgeon” medical device innovation. The company’s flagship product family, DuraSorb Monofilament Mesh is on the market and indicated for use in the reinforcement of soft tissues where weakness exists. DuraSorb was specifically designed for plastic, reconstructive, and general surgery and is US FDA 510(k) cleared and CE marked. SIA was formed in 2016 and is based in Chicago, Illinois.

Buy -

Seller(S) 1

SELLER

Ethicon Endo-Surgery

Cincinnati, Ohio, United States
Category Company
Sector Medical Products
DESCRIPTION

Ethicon Endo-Surgery (EES) has an endless supply on hand. A subsidiary of Johnson & Johnson, the company makes surgical devices and equipment for open surgeries and minimally invasive procedures in the areas of bariatrics, gastrointestinal health, gynecology, and surgical oncology.

DEAL STATS #
Overall 3 of 3
Sector (Medical Products) 3 of 3
Type (Divestiture) 3 of 3
State (California) 1 of 1
Country (United States) 2 of 2
Year (2023) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-02-13 Auris Health

Redwood City, California, United States

Auris Health, Inc. is a developer of robotic technologies, initially focused on lung cancer, with an FDA-cleared platform currently used in bronchoscopic diagnostic and therapeutic procedures. Redwood City, California. Auris Health was founded in 2007 and is based in Redwood City, California.

Buy $3.4B
Mergr

Product

Company

Legal